Target intelligence / Profile preview

SCN1A and SCN9A antisense RNA 1 (SCN1A-AS1)

Target: SCN1A-AS1
Molecular classification: Long non-coding RNA (lncRNA), natural antisense transcript (NAT)

Overview

SCN1A and SCN9A antisense RNA 1 (SCN1A-AS1) is a long non-coding RNA that is naturally transcribed antisense to the SCN9A gene, which encodes the Nav1.7 voltage-gated sodium channel critical for pain perception. SCN1A-AS1 is highly conserved between humans and mice, co-expressed in similar tissues, and shows regulatory activity specific to SCN9A. Experimental overexpression in cell lines leads to decreased levels of SCN9A mRNA, protein, and sodium currents, implicating this lncRNA in the modulation of neuronal excitability and pain thresholds. SCN1A-AS1 is not a receptor, enzyme, or classic druggable target, but may serve as a future therapeutic tool or disease susceptibility locus, especially in chronic pain disorders lacking coding gene mutations.

Other names: SCN1A-AS1SCN1ANATSCN1A-NATSCN1A natural antisense transcriptLOC102724058SCN1A-ASNR_110260 (GenBank transcript ID)

Mechanism of action

Not applicable / investigational only. Experimental overexpression of SCN1A-NAT reduces SCN9A (Nav1.7) sodium channel expression through antisense RNA-mediated mechanisms, possibly by RNA interference, mRNA destabilization, or transcriptional interference. No therapeutics exploit this mechanism directly to date; modulation of NATs is an experimental strategy only.

Biological functions

Gene expression regulation: Modulates expression of protein-coding genes, primarily through transcriptional and post-transcriptional regulation.Modulation of sodium channel activity: Negatively regulates SCN9A (Nav1.7) mRNA and protein expression, thus influencing neuronal excitability and pain signaling. Potentially involved in regulation of other sodium channel genes (e.g., SCN1A, SCN2A, SCN3A), though evidence supports specificity for SCN9A.

Disease associations

Pain disorders: Implicated in the regulation of pain thresholds and may be involved in chronic pain syndromes (e.g., inherited erythromelalgia, paroxysmal extreme pain disorder, small fiber neuropathy associated with SCN9A mutations).Epileptic syndromes: Genetic variants in related loci have been linked to epilepsy, but SCN1A-AS1 itself is not yet directly associated with specific epilepsy types.

Beyond the preview

Go deeper on SCN1A and SCN9A antisense RNA 1 (SCN1A-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCN1A and SCN9A antisense RNA 1 (SCN1A-AS1).

Explore the full profile